Interleukin 8 Inhibitor (IL8INH)

Reparixin

Interleukin 8 Inhibitor (IL8INH)
Reparixin, a specific interleukin-8 inhibitor, has no effects on inflammation during endotoxemia. Reparixin, being metabolized to ibuprofen, suppressed serum thromboxane B2 levels by 78 percent compared to baseline and control at 8 h. LPS-induced neutrophilia was not significantly affected by reparixin in human volunteers.
Consistently, reparixin did not alter the lymphocyte or monocyte counts and had no effect on LPS-induced systemic inflammation as measured by tumor necrosis factor alpha (TNF-alpha) or interleukin-6 (IL-6) release. Regulation of IL-8 receptors CXCR1 and 2 and the degranulation marker CD11b showed the expected kinetics. Reparixin had no effect on thrombin formation as measured by prothrombin fragment (F1+2). In contrast to previous studies with its metabolite ibuprofen, reparixin does not enhance inflammation in this model.

Organism species: Homo sapiens (Human)